BTIG Raises MDxHealth Price Target to $7, Maintains 'Buy' Rating

BTIG analyst Mark Massaro maintains a 'Buy' rating on MDxHealth (MDXH) with a revised price target of $7.00, an increase from $6.00, reflecting a 16.67% jump. The update comes as BTIG maintains its 'Buy' rating, indicating continued confidence in the company's performance and future prospects. MDxHealth provides actionable molecular diagnostic information for cancer diagnosis and treatment.